AbbVie diversifies for future growth

We continue to see attractive investment opportunities for our subscribers in top drug stocks—and that includes AbbVie Inc. At the same time, over the years, we’ve found that spinoffs are about as close as you can get to a sure thing in investing. It’s one… Read More

Pass on this ETF

B.A.D. ETF $12.04 (New York symbol BAD) invests globally in listed companies with exposure to betting, alcohol, and drugs (especially cannabis). The ETF also promotes itself as non-ESG (environmental, social and governance) and non-technology focused.
The fund launched on December 21, 2021, and charges investors a high management… Read More

Here’s two new ETFs for Canadian investors

This month we take a look at a new healthcare ETF from TD Asset Management, plus a very unique ETF from Horizons that focus on companies looking to develop psychedelic drugs for the treatment of mental illness.
TD Asset Management recently launched the TD Global… Read More

AbbVie’s diversification pays off

We continue to see attractive investment opportunities for our subscribers in top drug stocks—and that includes AbbVie Inc.
Over the years, we’ve found that spinoffs are about as close as you can get to a sure thing in investing. It’s one key reason why we think… Read More